Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
Status:
Terminated
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II
trial design to allow a rapid efficacy and toxicity assessment of potential therapies
(camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild
to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among
others.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborators:
Hospital General de Mexico Hospital General Dr. Manuel Gea González Instituto Nacional de Cardiologia Ignacio Chavez